TriangleDC/MM Fusion Vaccine (NCT07377435)
DC/MM Fusion Vaccine trial for Multiple Myeloma (NCT07377435). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for relapsed or refractory multiple myeloma, in adults eligible for standard BCMA CAR T cell therapy.
The idea: add a personalized cancer vaccine. The DC/MM fusion vaccine is an investigational agent that tries to help the immune system recognize and fight cancer cells. Patient cells are collected, and the vaccine is given with GM CSF, a growth factor, alongside the standard CAR T therapy.
This phase 1 study plans 25 patients and tracks safety first. At Beth Israel Deaconess Medical Center in Boston, Jacalyn Rosenblatt leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.